<DOC>
	<DOCNO>NCT00519467</DOCNO>
	<brief_summary>Drug resistance range antimalarial treatment become widespread Africa , South East Asia South America . Because rapid spread drug resistance threaten public health disaster area world comply WHO-Roll Back Malaria policy use Artemisinin-based combination therapy ( ACT ) , need develop new , safe , effective affordable ACT . Chlorproguanil-dapsone-artesunate ( CDA ) new ACT develop treatment uncomplicated falciparum malaria Africa .</brief_summary>
	<brief_title>Safety Efficacy Dose Artesunate Used Combination With LAPDAP Treatment Uncomplicated Falciparum Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Chlorproguanil</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<criteria>Presentation healthcare facility probable uncomplicated clinical malaria Adults age 18 60 year , child age 12 120 month Weight 5 85kg Pure [ microscopic ground ] screen P. falciparum parasitaemia child 25,000 100,000ul1 , adult 10,000 100,000ul1 . [ The parasitaemia range adult originally set 25,000 100,000µl1 change 10,000 100,000µl1 protocol amendment 3 date 05 May 2004 ] Written oral witness consent obtain subject , parent guardian Compliance requirement protocol include hospital stay 4 day 3 night regular blood sample fingerprick ( child ) via cannula ( adult ) A negative pregnancy test woman childbearing age enrolment Features severe/complicated falciparum malaria Known allergy sulphonamides Evidence concomitant infection time presentation ( include P. ovale P. malaria ) Any underlying disease would compromise diagnosis evaluation response study medication ( include clinical symptom immunosuppression , tuberculosis bacterial infection ) Treatment 28days prior screen sulfadoxine/pyrimethamine ( FANSIDAR , CELOXINE ) , sulfalene/pyrimethamine ( METAKELFIN ) , mefloquinesulfadoxinepyrimethamine ( FANSIMET ) , chloroquine* ( NIVAQUINE ) ; treatment 21days prior screen mefloquine , 7days prior screen amodiaquine , halofantrine , quinine ( full course ) , atovaquone proguanil , artemisinins , coartemether , tetracycline clindamycin , treatment 5 halflives prior screen drug potential antimalarial activity ( e.g . cotrimoxazole previous 60 hour ) Use investigational drug within 30 day 5 halflives ( whichever longer ) prior screen Previous participation study A positive pregnancy test enrolment , woman childbearing age take pregnancy test female subject breastfeed infant duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>dose-ranging study</keyword>
	<keyword>SB-714703</keyword>
	<keyword>artesunate ,</keyword>
	<keyword>malaria</keyword>
	<keyword>CDA ,</keyword>
	<keyword>chlorproguanil ,</keyword>
	<keyword>dapsone ,</keyword>
</DOC>